Syneron Medical Beats on Both Top and Bottom Lines

Syneron Medical (NAS: ELOS) reported earnings on Feb. 12. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Syneron Medical beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share expanded.


Gross margins expanded, operating margins dropped, net margins expanded.

Revenue details
Syneron Medical chalked up revenue of $72.8 million. The four analysts polled by S&P Capital IQ expected to see revenue of $70.6 million on the same basis. GAAP reported sales were 19% higher than the prior-year quarter's $61.0 million.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.11. The four earnings estimates compiled by S&P Capital IQ predicted $0.09 per share. GAAP EPS were $0.14 for Q4 compared to -$0.23 per share for the prior-year quarter.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 49.5%, 30 basis points better than the prior-year quarter. Operating margin was -2.3%, 4,090 basis points worse than the prior-year quarter. Net margin was 7.1%, 2,030 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $71.7 million. On the bottom line, the average EPS estimate is $0.12.

Next year's average estimate for revenue is $299.1 million. The average EPS estimate is $0.66.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 706 members out of 740 rating the stock outperform, and 34 members rating it underperform. Among 211 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 205 give Syneron Medical a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $16.38.

Is Syneron Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Syneron Medical Beats on Both Top and Bottom Lines originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Learn about investing from the comfort of your own home.

Portfolio Basics

Take the first steps to building your portfolio.

View Course »

Investment Strategies

Learn the strategies you need to build a winning portfolio

View Course »

Add a Comment

*0 / 3000 Character Maximum